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Mutations in the human methyl-CpG-binding protein geneMECP2
cause the neurological disorder Rett syndrome and some cases of
X-linked mental retardation (XLMR). We report that MeCP2 inter-
acts with ATRX, a SWI2/SNF2 DNA helicase/ATPase that is mutated
in ATRX syndrome (-thalassemia/mental retardation, X-linked).
MeCP2 can recruit the helicase domain of ATRX to heterochromatic
foci in livingmouse cells in a DNAmethylation-dependent manner.
Also, ATRX localization is disrupted in neurons ofMecp2-null mice.
Point mutations within the methylated DNA-binding domain of
MeCP2 that cause Rett syndrome or X-linked mental retardation
inhibit its interaction with ATRX in vitro and its localization in vivo
without affectingmethyl-CpG binding.We propose that disruption
of the MeCP2–ATRX interaction leads to pathological changes that
contribute to mental retardation.
DNA methylation  Rett syndrome  X-linked mental retardation
Epigenetic phenomena have recently been implicated in de-velopment of the brain (1). The proteinMeCP2, for example,
which binds to certain methylated CpG sites in the genome and
can recruit transcriptional corepressors (2–4), is essential for
normal brain function. Females heterozygous for mutations in
the X-linked MECP2 gene develop Rett syndrome (RTT), a
severe neurological disorder that becomes apparent within the
first 2 years of life (5–7). Mouse models of this disorder in which
theMecp2 gene is deleted also show a delayed-onset neurological
phenotype (8, 9). Conditional deletion of Mecp2 in the brain
alone causes indistinguishable symptoms, confirming that this
organ is most affected by absence of MeCP2 (8, 9). More
specifically, expression of MeCP2 in neurons alone is sufficient
to prevent the onset of the neurological phenotype (10). The
data suggest that MeCP2 is required to interpret the DNA
methylation signal in neurons, but little is known about the
molecular details of this essential role.
The function of a protein can be illuminated by identification
of its interacting partners. For example, the association of
MeCP2 with the corepressor molecule mSin3a established a link
between DNA methylation and deacetylation of chromatin (2,
11). Subsequently, MeCP2 has been reported to interact with
several other protein partners, including histone H3 lysine 9
methyltransferase activity (12), c-Ski (13), DNMT1 (14), CoRest
(15), LANA (16), PU1 (17), splicing factors (18), Y box-binding
protein 1 (19), Brm (20), and RNA (21). The relative importance
of these interactions, in particular their contributions to the
function of MeCP2 in neurons, remains to be clarified. In this
study, we performed a further search for proteins that interact
with MeCP2. We identified ATRX (22, 23), a SWI2/SNF2 DNA
helicase/ATPase that is mutated in a separate neurological
disorder, ATRX syndrome (-thalassemia/mental retardation,
X-linked). We mapped the interaction sites on each protein and
demonstrated that MeCP2 could target the C-terminal domain
of ATRX to heterochromatic foci in cultured mouse cells.
Strikingly, the heterochromatic localization of ATRX (24) was
disturbed in neurons of the Mecp2-null brain. Moreover, muta-
tion in the human MECP2 gene that cause mental retardation
were found to inhibit the MeCP2–ATRX interaction. These
genetic findings raise the possibility that MeCP2 and ATRX
collaborate during brain development, and that mutations that
disturb their interaction interfere with neuronal function.
Results
ATRX Associates with MeCP2. To identify MeCP2-interacting pro-
teins, we performed a yeast two-hybrid screen. Intact MeCP2
caused transcriptional inhibition in yeast because of sequences in
the C-terminal half of the protein. We therefore used the
N-terminal half of the e2 isoform of rat MeCP2 (amino acids
1–206) as bait. Human and rat MeCP2 are 98% identical in
sequence from amino acid 16 to 206 (human). Screening of a
human fetal brain library yielded 67 clones that activated theHIS
reporter gene, of which 12 verified clones matched the human
ATRX cDNA. We defined the region of ATRX that interacted
with MeCP2 by deletion analysis. An ATRX polypeptide that
contained the C-terminal helicase motif (2010–2280) interacted
with MeCP2 as assayed with ADE andHIS reporters in the yeast
PJ69 strain, but shorter polypeptides failed to activate either
reporter (Fig. 1a). The interaction strength was quantified in the
MaV203 strain with a lacZ reporter (data not shown). We next
asked whether MeCP2 interacted with ATRX in vitro using
GST-pulldown assays with recombinant proteins. In vitro trans-
lated ATRX (1201–2190) bound to the immobilized GST-
MeCP2 fusion protein but not to GST alone (Fig. 1b). The
related protein Lsh/HELLS (25), which contains a SWI2/SNF2
DNA helicase domain that shows 32% amino acid identity to
ATRX, did not bind to GST-MeCP2 [supporting information
(SI) Fig. 6]. By testing a panel of GST fusion proteins containing
truncated MeCP2 fragments (Fig. 1b and SI Fig. 7), we estab-
lished that the ATRX-binding domain lies between amino acids
108 and 169 and therefore overlaps the methyl-CpG-binding
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domain ofMeCP2 (Fig. 1c) (26). To test for interactions between
the full-length proteins, we exposed a recombinant MeCP2-GST
fusion protein to a nuclear extract from mouse brain that had
been solubilized by extensive sonication. Western blotting es-
tablished that endogenous ATRX was bound by full-length
MeCP2 (Fig. 1d). The interaction was insensitive to DNase I or
RNase A treatments, indicating that it is not mediated by nucleic
acid (Fig. 1d).
We asked whether MeCP2 and ATRX interact in vivo by
cotransfecting expression constructs that encoded HA-tagged
full-length MeCP2 and a GFP-ATRX (1201–2492) fusion pro-
tein including a nuclear localization signal into mouse L cells.
Both anti-HA and anti-MeCP2 antibodies coprecipitated GFP-
ATRX, whereas anti-GFP and anti-ATRX antibodies both
reproducibly coimmunoprecipitated HA-MeCP2 (Fig. 1e). An
irrelevant antibody, anti-myc, precipitated neither MeCP2 nor
ATRX (Fig. 1e). The results demonstrate that ATRX and
MeCP2 can interact in vivo. We attempted to perform coimmu-
noprecipitation of endogenous proteins from mouse brain.
ATRX was insoluble even after extraction of nuclei with 2 M salt
(see SI Fig. 8) and has been classified as a ‘‘matrix-associated’’
protein (27). Under conditions where ATRX could be solubi-
lized (1 M urea/300 mM NaCl/1% Nonidet P-40), we were
unable to detect coimmunoprecipitation with MeCP2 (P. Skene,
unpublished observations).
Studies have established that, in mouse cells, both MeCP2 and
ATRX localize to pericentromeric heterochromatin (24, 28, 29).
MeCP2 localization depends on binding to abundant methyl-CpG
sites in these nuclear foci, whereas ATRX localization may require
interactionwith heterochromatin protein 1 (HP1) via itsN-terminal
domain (24). To test whether MeCP2 affects ATRX localization,
we analyzed the localization of each endogenous protein in mouse
fibroblasts lacking detectable DNA methylation [P-M- cells (30)].
As expected (29), MeCP2 was not efficiently targeted to the
heterochromatic nuclear foci in nonmethylated cells, whereas cor-
rect targeting was seen in control P- cells (Fig. 2a). ATRX was
concentrated in heterochromatin of both P- and P-M- fibroblasts
(Fig. 2a), demonstrating that heterochromatic targeting of ATRX
in these cells does not depend on MeCP2 localization. We con-
firmed that the N terminus of ATRX was sufficient for correct
localization in wt cultured fibroblasts by showing that the N
terminus of ATRX, which lacks the MeCP2 interaction domain,
was targeted to heterochromatic foci when fused to GFP ]GFP-
ATRX (1–745); Fig. 2b Top). As the dominance of the N-terminal
domain would mask a role of MeCP2 in ATRX targeting, we
expressed a GFP-ATRX (NLS1916–2492) fusion protein lacking
the N-terminal domain but retaining the C-terminal DNA helicase
motif that binds MeCP2. This protein showed a dispersed nuclear
distribution (Fig. 2b Middle). Coexpression of the ATRX
(NLS1916–2492) protein with HA-taggedMeCP2, however, led to
efficient targeting of ATRX to heterochromatic foci (Fig. 2b
Bottom). When the same cotransfection was performed by using
DNA methylation-deficient P-M- cells, neither MeCP2 nor the
C-terminal fragment of ATRX localized to the heterochromatic
foci (Fig. 2c). These results raise the possibility that ATRX recruit-
ment in vivo can involve both MeCP2 and DNA methylation.
ATRX Delocalization in theMecp2-Null Brain.TheATRXN terminus
is the dominant signal for nuclear sublocalization in cultured
fibroblasts (Fig. 2b), but MeCP2 is not highly expressed in these
cells. Knowing that MeCP2 is abundant in neurons (31, 32), we
asked whether ATRX localization in the brains of Mecp2-null
mice (9) was affected by absence of MeCP2. In the wild-type
adult brain, ATRX and MeCP2 were both concentrated in
heterochromatic foci (70–80% of nuclei; Fig. 3a). In each of four
Mecp2-null brains from animals with overt neurological symp-
toms (8–11 weeks postnatal age), however, only a minority of
nuclei displayed focal ATRX (15%; see Fig. 4a). Diffuse
ATRX staining was seen reproducibly in mutant animals in the
dentate gyrus of the hippocampus (Fig. 3b and SI Fig. 9), the
cortex (Fig. 3c), and other regions of the Mecp2-null brain. In
contrast to the vast majority of brain cells, tissues in which
MeCP2 is less abundant (e.g., kidney and heart) showed no
Fig. 1. MeCP2 interacts with ATRX. (a) Yeast two-hybrid assays identified a
region of ATRX that interacts with MeCP2. The diagram depicts ATRX and its
domains. Fragments 1915–2492 and 1948–2492 (amino acids numbered from
the N terminus) were original clones from the library screen. Symbols,,
or  indicate the strength of the MeCP2 interaction based on expression of
yeast HIS, ADE, and LacZ reporters (data not shown). The MeCP2 interaction
domain (MID) is marked. (b) The ATRX-interaction region overlaps the MBD of
MeCP2. The MeCP2 region that binds ATRX was identified by GST pulldown by
using a deletion series of MeCP2-GST fusion proteins (for polyacrylamide gel
of proteins, see SI Fig. 7) incubated with in vitro-translated [35S]-labeled ATRX
fragment 1201–2190 (bracket; a). The input lane (Top) contained 25% of
labeled protein used for the pull-down assay. (c) Summary of GST-pulldown
showing presence () or absence () of an ATRX interaction leading to
identification of an ATRX-interacting domain (AxID). Point mutations that
inhibit ATRX binding (R133C, A140V, and R168X; see Fig. 5) are marked by
arrows. (d) Native ATRX in nuclear extracts from brain is ‘‘pulled down’’ by
immobilized full-length MeCP2. A MeCP2-GST fusion protein (M) or GST alone
(G) were immobilized on glutathione beads and mixed with extract. Bound
proteins and input (In; 10%) were separated and probed with anti-ATRX
antibody on a Western blot. (e) CoIP of HA-tagged MeCP2 and GFP-fusion
ATRX(NLS1201–2492) expressed transiently in mouse L cells. ‘‘Input’’ lane
shows 10% of input amount. Antibodies used for coIP and blot visualization
are labeled above and beside the figure, respectively.
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apparent difference in ATRX localization in the presence or
absence of MeCP2 (SI Fig. 10).
Loss of ATRX-positive foci was not due to reduced hetero-
chromatic integrity, because DAPI bright spots and anti-
trimethyl histone H3 lysine 9 immunostaining were indistin-
guishable from wt in mutant brain sections that lacked focal
ATRX staining (Fig. 4 b and c). The heterochromatin protein
HP1 also showed a punctate localization that was indistinguish-
able between thewt andmutant dentate gyrus (SI Fig. 11). These
findings suggest that heterochromatin structure is normal in
Mecp2-null cells. The absence of a correlation between ATRX
and HP1 staining also indicates that any influence of HP1 on
ATRX localization (33) is minimal in these brain cells. Diffuse
ATRX staining was not due to reduced ATRX expression,
because wt and Mecp2-null brains expressed equivalent levels of
ATRX protein by Western blot (SI Fig. 12). We also tested the
possibility that the cellular composition of the hippocampus was
radically altered in the mutants, rendering these regions non-
equivalent in the wt and mutant brains. Morphologically, the
hippocampus appeared identical in wt and Mecp2-null brains.
Immunostaining confirmed that nuclei in the dentate gyrus with
delocalized ATRX were NeuN-positive postmitotic neurons, as
found in equivalent regions of the wt hippocampus (SI Fig. 13).
Our results are compatible with the hypothesis that ATRX
localization to heterochromatic foci in neurons is directed by the
MeCP2–ATRX interaction demonstrated elsewhere in this
study, although we are unable to exclude the possibility that the
effect is an indirect consequence of MeCP2 deficiency.
MeCP2 abundance has been shown to increase dramatically in
neurons as they mature (31), leading to an estimated average
concentration of 6  106 molecules per brain cell (see ref. 29).
We asked whether ATRX was incorrectly localized in newborn
(postnatal day 1) Mecp2-null brain, where MeCP2 is usually
present at relatively low concentrations. The results showed no
obvious ATRX delocalization (SI Fig. 14), suggesting that
MeCP2-dependent ATRX targeting is a feature of mature
neurons only.
Certain MECP2 Mutations Affect the ATRX Interaction but Not DNA
Binding. The disruption of ATRX localization in the Mecp2-null
mouse brain suggested that humanMECP2mutations that cause
neurological disorders might affect the interaction with ATRX.
We tested three mutant forms of MeCP2 (R106W, R133C, and
R168X) that occur in RTT, one mutant whose clinical signifi-
Fig. 2. ATRX localizes to heterochromatic foci in cultured mouse cells lacking
DNA methylation, but exogenous MeCP2 can direct the ATRX C-terminal
domain to heterochromatin in a DNA methylation-dependent manner. (a)
Localization of endogenous ATRX in mouse fibroblasts is normally indepen-
dent of MeCP2. Control P cells and the DNA methylation-deficient P-M cells
were immunostained with anti-ATRX and anti-MeCP2 antibodies and coun-
terstained with Hoechst 33258. (b) The C-terminal region of ATRX is targeted
to heterochromatin by MeCP2. Constructs expressing GFP fused to the ATRX
N terminus (1–745) or the ATRX C terminus (1916–2492), including an SV40
NLS, were transfected singly, or in combination with full-length MeCP2, into
mouse L cells. (c) Targeting of the ATRX C terminus by MeCP2 depends on DNA
methylation. ATRX (NLS1916–2492) and HA-MeCP2 were transiently coex-
pressed in control P or DNA methylation-deficient P-M cells. Localization was
monitored by using anti-GFP and anti-HA antibodies. (Scale bars: 10 m.)
Fig. 3. Mislocalization of endogenous ATRX in the Mecp2-null mouse brain.
(a) Immunostaining of ATRX, MeCP2, and DNA (DAPI) inwthippocampus (CA1
region) confirms colocalization of MeCP2 and ATRX in neuronal nuclei (see
yellow stain in merge). (b) Loss of ATRX localization in the Mecp2-null hip-
pocampus. Speckled nuclear staining of ATRX coincides with MeCP2 foci in the
wtdentate gyrus (for merged images, see SI Fig. 9), but dispersed nuclear ATRX
staining is reproducibly seen in the Mecp2-null brain. (c) Immunostaining of
ATRX in cortical neurons of wt and Mecp2/y brains. (Scale bars: 10 m.)
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cance is not well characterized (R111G) and one mutant
(A140V) that occurs in male XLMR (34–36), for binding to
ATRX by using the GST pull-down assay. The relative ATRX
binding affinities of R111G and R106W were indistinguishable
fromwt, but A140V, R133C, and R168X bound very weakly (Fig.
5a). Analysis of the DNA-binding activity of the same mutant
polypeptides by bandshift analysis showed that the methyl-CpG
affinity was abolished by the R106W and R111G mutations and
slightly reduced compared with wild type by the R168Xmutation
(summary in Fig. 5a; see SI Fig. 15). Neither the R133C nor the
A140V mutations affected binding to methylated DNA, al-
though weak binding of R133C to the nonmethylated probe was
observed, suggesting reduced specificity for methylatedDNA (SI
Fig. 15). In summary, the A140V, R168X, and, to a lesser extent,
R133C mutations reduce the affinity of MeCP2 for ATRX in
vitro without major effects on its affinity for methylated DNA.
We next asked whether in vivo-expressed full length MeCP2
carrying these mutations could (i) localize to methyl-CpG-rich
heterochromatic foci; (ii) recruit ATRX (NLS1916–2492) to
these foci. The R168X mutant was not assayed because it lacks
a nuclear localization signal. R106W and R111G polypeptides
neither localized themselves nor recruited ATRX to pericentric
heterochromatin (Fig. 5b), in agreement with Fig. 5a and
previous findings (37). In contrast, R133C and A140V mutants
targeted heterochromatin (Fig. 5b), as predicted by their affinity
for methyl-CpG in vitro (Fig. 5a), but neither mutant protein
could recruit ATRX (NLS1916–2492) to heterochromatin (Fig.
5b). We conclude that the clinically relevant R133C and A140V
mutations, which have no discernable effect on targeting of
MeCP2 to methylated sites in this assay, disrupt the interaction
between MeCP2 and ATRX in vitro and in vivo.
Discussion
Our data show that MeCP2 and ATRX, two proteins that are
required for normal brain function, interact in vitro and in living
cells. The interaction is supported by five independent lines of
evidence: (i) a positive yeast two-hybrid assay; (ii) in vitro GST
pulldowns; (iii) coimmunoprecipitation of the in vivo coex-
Fig. 4. Heterochromatic foci persist in the Mecp2-null brain but do not
sequester ATRX. (a) Dentate gyrus nuclei (100 per section, three brains per
genotype) were graded for ATRX localization: predominantly heterochro-
matic staining (het.), heterochromatic plus diffuse staining (part.), and diffuse
staining only (diff.). Significance of differences between wt (open bars) and
mutant (shaded bars) are denoted by P values. (b) Dentate gyrus was also
graded for staining with antibodies against trimethyl histone H3 lysine 9. (c)
ATRX is delocalized in mutant nuclei that retain normal histone H3 lysine 9
trimethylation of heterochromatic foci. (Scale bar: 10 m.)
Fig. 5. Mutations in human in the MBD of human MeCP2 that cause mental
retardation disturb the MeCP2–ATRX interaction without affecting methyl-
CpG binding. (a) A GST fusion of ATRX (1915–2492) was immobilized and
exposed to in vitro-translated [S35]-labeled MeCP2 (1–206) with the mutations
indicated at the left. Shown is 10% of input, the amounts retained by ATRX
(1915–2492) and by GST. Densitometric results (average of three experiments)
are expressed relative towt (% bound) together with P values (Student t test).
The ‘‘mCpG binding’’ column summarizes the methyl-CpG binding as assayed
in SI Fig. 15. (b) MeCP2 mutants A140V and R133C target heterochromatic foci
but cannot direct ATRX to heterochromatin. HA-tagged full-length mutant
MeCP2 forms were coexpressed with GFP-ATRX (NLS1916–2492) fusion pro-
teins in mouse fibroblasts. Localization was monitored by immunostaining
using anti-HA (MeCP2) and anti-GFP (ATRX) antibodies. In the merge, Hoechst,
ATRX, and MeCP2 are blue, green, and red, respectively. R133C and A140V
mutants colocalize with Hoechst bright spots (pink spots, triple merge), but
ATRX staining is diffuse (absence of yellow spots, double merge). Note that
MeCP2 R111G partially localizes to nucleoli.
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pressed proteins; (iv) MeCP2-dependent and DNAmethylation-
dependent targeting of the ATRX C-terminal domain in vivo to
nuclear heterochromatic foci; and (v) widespread delocalization
of ATRX in neuronal nuclei of Mecp2-null mice.
Certain MECP2 mutations that cause XLMR interfere with
the MeCP2–ATRX interaction. Specifically, the A140V and
R133C mutant proteins localize efficiently to heterochromatic
foci, but are unable to recruit the C terminus of ATRX to these
sites. Despite the overlap of the MBD and ATRX-binding
domains of MeCP2, only binding to ATRX is affected by the
A140V mutation, which therefore uncouples the DNA- and
ATRX-binding functions of MeCP2. The R133C and R168X
mutations also reduce binding to ATRX, but both may affect
additional functions of MeCP2, because the former enhances
binding to nonmethylated DNA, and the latter eliminates the
C-terminal two-thirds of MeCP2. Interestingly, the R133C mu-
tation, although frequent in RTT patients, tends to cause a
relatively mild phenotype, which may be related to incomplete
loss of methylated DNA binding. The A140V mutation is
therefore of particular interest, because its only measurably
altered property is loss of the ability to interact with ATRX.
A140V is not an RTT mutation but has been reported in
hemizygous males of several independent XLMR families (34–
36, 38). The A140V phenotype is evidently less severe than that
of mutations causing RTT, because heterozygous females are
either normal or occasionally suffer mild mental retardation. An
intriguing possibility is that inappropriate targeting of ATRX
contributes to the neurological phenotype of RTT patients and
Mecp2-null mice.
In cultured cells, it has been demonstrated that the ATRX
N-terminal region, which contains the conserved PHD domain,
is sufficient to target the protein to heterochromatic foci (33). In
mature MeCP2-deficient neurons, however, ATRX adopts a
diffuse nuclear distribution, suggesting that the N terminus is not
sufficient for localization in these cells. Dispersal of ATRX is not
caused by a general loss of heterochromatin integrity, because
both trimethylation of histone H3 lysine 9 and localization of
HP1 remain normal in these neurons. A previous report found
that overexpressed MeCP2 in muscle cells alters heterochroma-
tin aggregation (39), but neither the number [Mecp2/y mean 
5.33 (SD  1.46); wt mean  4.97; (SD  1.81); n  75 and 71]
nor the distribution of nuclear foci differed noticeably between
wt and Mecp2-null neurons in 8- to 11-week-old mice. In the
absence of gross structural alterations in Mecp2-null neuronal
heterochromatin, it seems that loss of ATRX targeting in
neurons depends on MeCP2 rather than the N-terminal domain.
The reasons for this altered dependence are currently unknown,
but it is conceivable that either ATRX or its usual targeting
partner (perhaps HP1) are posttranslationally modified in neu-
rons, thereby preventing interaction. Alternatively, the normal
ATRXN-terminal ligand protein may be inaccessible in neurons
because of physical sequestration or saturation of binding sites
by competing proteins. It is also possible that the exceptionally
high abundance of MeCP2 in brain (29) gives it the dominant
role in ATRX localization, particularly if the abundance of
ATRX itself exceeds that of its conventional targeting proteins
in mature neurons.
Patients with mutations in ATRX exhibit severe psychomotor
retardation, characteristic facial features, -thalassaemia, and
genital abnormalities (40). Of relevance is the observation that
conditional deletion of ATRX in the mouse forebrain causes a
major decrease in forebrain size because of a reduction in the
number of neuronal precursors surviving to reach the cortex
(41). These findings demonstrate the importance of ATRX in
early neuronal development and raise the possibility that its
continued presence is important in mature neurons, where
MeCP2 is also required (31). Little is known of the normal
function of ATRX, but it belongs to a family of proteins that
share the Snf2 motor domain. Several family members can
modify the structure of nucleosomal chromatin (42), and ATRX
has itself been shown to modify chromatin in an ATP-dependent
manner in vitro (43). In addition, ATRX interacts with the
chromatin-associated proteins HP1 (24, 44), the polycomb
group protein EZH2 (45) and the transcription cofactor Daxx
(43, 46). Heterochromatic foci provide a convenient visual assay
for correct localization of ATRX, but major genomic sites of
ATRX function may be euchromatic. A speculative hypothesis is
that ATRX contributes to epigenetic regulation of certain
MeCP2-bound genes. Several other mammalian candidates are
known, including the rodent brain-derived neurotrophic factor
(Bdnf ) gene (47, 48) and others that are reportedly misregulated
in the absence of MeCP2 (49–51). The next step is to determine
whether these and other emerging MeCP2 targets are affected
directly or indirectly by ATRX.
Materials and Methods
Construction of Plasmids, Cell Lines, Protein Immunostaining, Extrac-
tion of Nuclear Proteins, GST Pulldowns of Endogenous ATRX, and
Western Blotting. For additional information on these topics, see
SI Methods.
Yeast Two-Hybrid Screening. A human fetal brain yeast two-hybrid
library constructed in prey vector pACT2 (Clontech, Palo Alto,
CA) was transformed into yeast PJ69. The bait constructs were
transformed to PJ69a and subsequently mated with the pretrans-
formed library in yeast PJ69. Approximately 107 independent
clones were screened. Initial screening was performed by using
histidine-minus SD plates, on which only HIS-expressing yeast can
grow, according to UserManual PT3183–1 (Clontech). Interaction
was confirmed in yeast PJ69 on adenine-minus SD plates by using
the GAL2-ADE2 reporter. To quantitatively measure the strength
of interaction by using a LacZ reporter, prey and bait plasmids were
cotransformed into yeast MaV203(MAT) (GIBCO BRL, Carls-
bad, CA). The activity of -galactosidase was measured in liquid
culture by using the ONPG substrate as described in ProQuest
Two-Hybrid System Instruction Manual (GIBCO BRL). Neither
theMeCP2 bait nor theATRXprey constructs could alone activate
the yeast reporters.
GST Pull-Down Assay.Expression and purification of GST–MeCP2
and GST-ATRX(1915–2492) fusion proteins were described (4,
26). [35S]methionine-labeled ATRX fragment (amino acid 1201–
2190) and MeCP2 fragment (amino acid 1–206) were generated
by using a coupled transcription–translation T7 RNA polymer-
ase TNT system (Promega, Madison, WI). GST fusion proteins
(3 g) were first bound to glutathione–Sepharose beads. For
pulldown with GST-MeCP2 fusion protein, [35S]-labeled ATRX
was incubated with immobilized GST fusion protein in 100 l of
binding buffer (20 mM Hepes, pH 7.9/0.1 M NaCl/1 mM
EDTA/0.5 mM DTT/10% glycerol/0.1% Triton X-100/1 mg/ml
BSA/protease inhibitor mixture) at 4°C for 2 h, and beads were
subsequently washed with RIPA buffer (50 mM Tris, pH 8.0/150
mM NaCl/1% Nonidet P-40/0.1% SDS/protease inhibitor mix-
ture). For pulldown with the GST-ATRX fusion, [35S]-labeled
MeCP2 or its mutant derivatives were incubated with immobi-
lized GST fusion protein in 400 l of binding buffer at 4°C for
2 h, and beads were subsequently washed with 0.2 M NaCl
washing buffer (20 mMHepes, pH7.9/0.2 M NaCl/1 mM EDTA/
0.5 mM DTT/0.1% Triton X-100/10% glycerol). Bound proteins
were eluted in Laemmli loading buffer, fractionated by SDS/
PAGE, and detected by autoradiography or by PhosphorImager.
For GST pulldown of endogenous ATRX, see SI Methods.
DNA Binding Assay. Affinity purified MeCP2-GST fusion protein
was incubated on ice with a 73-bp 32P-labeled DNA probe 5
GTTTTCCCAGTCACTACCGCAGCACGGTGGGGGG
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CCGGAGTTAAGGACTCGTTGTCGTCATAGCTGTT
TCCTG that was either methylated at a single central HpaII site
(bold) or nonmethylated. MeCP2 bound probe was separated
from free probe on 5% acrylamide gel by using a standard
protocol (26).
Coimmunoprecipitation (coIP). L cells were transfected with HA-
MeCP2 expressing plasmid pCMV/HA-MeCP2 and GFP-NLS-
ATRX expressing plasmid pcDNA3/GFP-ATRX(NLS1201–
2190) by using the transfection reagent Lipofectamine2000
(Invitrogen, Carlsbad, CA). After 2 d, nuclei were isolated, and
nuclear extract was prepared (4). Nuclear extract was precleared
by incubation with protein A-Sepharose (Amersham Pharmacia,
Piscataway, NJ) before coIP. Aliquots (100 g of protein) of
precleared nuclear extract were incubated for 2 h at 4°C, with 20
l of affinity-purified HA-Tag polyclonal antibody (Clontech),
5 l of GFP antiserum (Living colors full-length A.v. polyclonal
antibody; Clontech), 5 l of MeCP2 antiserum (674) (4), 20 l
of affinity-purified anti-ATRX antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA) or with 20 l of affinity-purified
anti-myc antibody (Invitrogen). The final volume was 500 l in
CSK buffer (10 mM Pipes, pH6.8/100 mM NaCl/3 mM MgCl2/1
mM EDTA/0.5% Triton X-100/EDTA-free protease inhibitors).
Antibody-boundmaterial was pelleted with protein A-Sepharose
(Amersham Pharmacia), washed three times with RIPA buffer
[150 mM NaCl/1% Nonidet P-40/50 mM Tris, pH 8.0/0.1%
SDS/1 Complete Protease inhibitors (EDTA-free; Roche,
Indianapolis, IN)]. Immunoprecipitated material was detected
by Western blot using rat anti-HA high-affinity antibody
(Roche) and mouse anti-GFP antibody (Roche).
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